Media Advisory: Event Invitation and Photo Opportunity - Bayer and Versant Partner to Create Next-Generation Regenerative Medicine Company

Second-largest series A investment for a biotech company

TORONTO, Dec. 8, 2016 /CNW/ - Bayer AG and Versant Ventures are set to make an announcement on Monday, December 12, to launch a new company to develop best-in-class therapies to cure a range of diseases. The company will have Canadian operations based in Toronto's MaRS Discovery District.

On December 12 you are invited to join Bayer, Versant Ventures, The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, and Premier Kathleen Wynne to learn more about the scientific innovation and what this investment means to Toronto, Canada, and the world.

WHAT:	Announcement by Bayer and Versant Ventures on partnership to create next-generation regenerative medicine company
WHERE:	MaRS Discovery District, West Atrium 101 College Street, Toronto
WHEN:	Monday, December 12, 2016
	8:30 a.m. – Media Registration 9:00 a.m. – Announcement 9:30 a.m. – Photo and Interview opportunities
WHO:	Speakers
	The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development The Honourable Kathleen Wynne, Premier of Ontario Alok Kanti, President and CEO, Bayer Inc. and Senior Bayer Representative in Canada Dr. rer. Nat. Axel Bouchon, head of The Bayer Lifescience Center Jerel Davis, Managing Director, Versant Ventures Dr. Gordon Keller, Director, McEwen Centre for Regenerative Medicine, University Health Network

SOURCE Bayer AG

To RSVP for the event and/or request an interview, please contact: Andrea Chrysanthou, Global Public Affairs, 416-597-3486, [email protected]; Andrea Ellison, Global Public Affairs, 647-943-0275, [email protected]